PMID- 29623394
OWN - NLM
STAT- MEDLINE
DCOM- 20180703
LR  - 20200715
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 97
IP  - 8
DP  - 2018 Aug
TI  - Evaluation of Revised International Staging System (R-ISS) for 
      transplant-eligible multiple myeloma patients.
PG  - 1453-1462
LID - 10.1007/s00277-018-3316-7 [doi]
AB  - The International Myeloma Working Group has proposed the Revised International 
      Staging System (R-ISS) for risk stratification of multiple myeloma (MM) patients. 
      There are a limited number of studies that have validated this risk model in the 
      autologous stem cell transplant (ASCT) setting. In this retrospective study, we 
      evaluated the applicability and value for predicting survival of the R-ISS model 
      in 134 MM patients treated with new agents and ASCT at the Mayo Clinic in Arizona 
      and the University Hospital of Salamanca in Spain. The patients were reclassified 
      at diagnosis according to the R-ISS: 44 patients (33%) had stage I, 75 (56%) had 
      stage II, and 15 (11%) had stage III. After a median follow-up of 60 months, 
      R-ISS assessed at diagnosis was an independent predictor for overall survival 
      (OS) after ASCT, with median OS not reached, 111 and 37 months for R-ISS I, II 
      and III, respectively (P < 0.001). We also found that patients belonging to R-ISS 
      II and having high-risk chromosomal abnormalities (CA) had a significant shorter 
      median OS than those with R-ISS II without CA: 70 vs. 111 months, respectively. 
      Therefore, this study lends further support for the R-ISS as a reliable 
      prognostic tool for estimating survival in transplant myeloma patients and 
      suggests the importance of high-risk CA in the R-ISS II group.
FAU - Gonzalez-Calle, Veronica
AU  - Gonzalez-Calle V
AUID- ORCID: 0000-0002-5493-6707
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
AD  - Hematology Department, University Hospital of Salamanca, Salamanca, Spain.
FAU - Slack, Abigail
AU  - Slack A
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
FAU - Keane, Niamh
AU  - Keane N
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
FAU - Luft, Susan
AU  - Luft S
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
FAU - Pearce, Kathryn E
AU  - Pearce KE
AD  - Laboratory Genetics/Cancer Center Mayo Clinic, Rochester, MN, USA.
FAU - Ketterling, Rhett P
AU  - Ketterling RP
AD  - Laboratory Genetics/Cancer Center Mayo Clinic, Rochester, MN, USA.
FAU - Jain, Tania
AU  - Jain T
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
FAU - Chirackal, Sintosebastian
AU  - Chirackal S
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
FAU - Reeder, Craig
AU  - Reeder C
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
FAU - Mikhael, Joseph
AU  - Mikhael J
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
FAU - Noel, Pierre
AU  - Noel P
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
FAU - Mayo, Angela
AU  - Mayo A
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
FAU - Adams, Roberta H
AU  - Adams RH
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
FAU - Ahmann, Gregory
AU  - Ahmann G
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
FAU - Braggio, Esteban
AU  - Braggio E
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
FAU - Stewart, A Keith
AU  - Stewart AK
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
AD  - Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Bergsagel, P Leif
AU  - Bergsagel PL
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA.
FAU - Van Wier, Scott A
AU  - Van Wier SA
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
FAU - Fonseca, Rafael
AU  - Fonseca R
AD  - Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA. 
      fonseca.rafael@mayo.edu.
AD  - Hematology Department/Transplant Center Mayo Clinic, Phoenix, AZ, USA. 
      fonseca.rafael@mayo.edu.
AD  - MAYO CLINIC, 5777 East Mayo Boulevard, Phoenix, AZ, 85054, USA. 
      fonseca.rafael@mayo.edu.
LA  - eng
GR  - P50 CA186781/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20180406
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Induction Chemotherapy
MH  - Maintenance Chemotherapy
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*diagnosis/mortality/pathology/therapy
MH  - Neoplasm Staging/*methods
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Transplantation, Autologous
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Autologous transplantation
OT  - Myeloma
OT  - Prognostic factor
OT  - R-ISS
EDAT- 2018/04/07 06:00
MHDA- 2018/07/04 06:00
CRDT- 2018/04/07 06:00
PHST- 2017/04/28 00:00 [received]
PHST- 2018/03/22 00:00 [accepted]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/07/04 06:00 [medline]
PHST- 2018/04/07 06:00 [entrez]
AID - 10.1007/s00277-018-3316-7 [pii]
AID - 10.1007/s00277-018-3316-7 [doi]
PST - ppublish
SO  - Ann Hematol. 2018 Aug;97(8):1453-1462. doi: 10.1007/s00277-018-3316-7. Epub 2018 
      Apr 6.